Provided by Tiger Fintech (Singapore) Pte. Ltd.

Qudian Inc.

2.74
-0.0600-2.14%
Post-market: 2.73-0.0097-0.35%16:09 EST
Volume:279.93K
Turnover:777.56K
Market Cap:518.97M
PE:102.18
High:2.83
Open:2.80
Low:2.73
Close:2.80
Loading ...

Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Non-Muscle Invasive Bladder Cancer (SURF302)

PR Newswire
·
10 Jan

Samsung Display to Unveil QD-OLED Panels at CES 2025

MT Newswires Live
·
07 Jan

MicroCloud Hologram Inc. Develops Semiconductor Quantum Dot Hole Spin Qubit Technology, Advancing the Frontiers of Quantum Computing

PR Newswire
·
30 Dec 2024

Asian Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading

MT Newswires Live
·
23 Dec 2024

Aadi Bioscience Leads 3 Promising US Penny Stocks

Simply Wall St.
·
23 Dec 2024

InflaRx Announces First Patient Dosed in Phase 2a Study for Oral C5aR Inhibitor INF904

GlobeNewswire
·
20 Dec 2024

Rigel Highlights Initial Data from Ongoing Phase 1b Study Evaluating R289 in LR-MDS at the 66th ASH Annual Meeting and Exposition

PR Newswire
·
10 Dec 2024

Enanta Pharmaceuticals Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV)

Business Wire
·
09 Dec 2024

C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader

GlobeNewswire
·
09 Dec 2024

Xenon Showcases New Long-Term Azetukalner Data from X-TOLE OLE Study in FOS at AES 2024

GlobeNewswire
·
07 Dec 2024

Recursion announces first patient dosed in Phase 1/2 clinical study of REC-1245, a potential first-in-class, RBM39 degrader for Biomarker-Enriched Solid Tumors and Lymphoma

GlobeNewswire
·
03 Dec 2024

Asian Equities Traded in the US as American Depositary Receipts Rise Sharply in Monday Trading

MT Newswires Live
·
02 Dec 2024

Revolution Medicines Provides Clinical Updates from its RAS(ON) Inhibitor Portfolio

GlobeNewswire
·
02 Dec 2024

Qudian Up Over 22%, On Pace for Highest Close Since March 2021 -- Data Talk

Dow Jones
·
27 Nov 2024

Qudian Third Quarter 2024 Earnings: EPS: CN¥0.73 (vs CN¥0.84 loss in 3Q 2023)

Simply Wall St.
·
24 Nov 2024

Qudian: Q3 Earnings Snapshot

Associated Press Finance
·
22 Nov 2024